Abstract
Background: Cigarette smoking is a major risk factor for several chronic diseases. Epidemiological data indicate the use of smokeless tobacco (ST) is associated with significantly lower risk for smoking-related diseases compared to cigarettes. Several biomarkers of exposure (BioExp) and effect (BioEff) associated with smoking and use of moist snuff (ST) were evaluated.
Methods: A single site, cross-sectional clinical study enrolled three groups of generally healthy male smokers (SMK), moist snuff consumers (MSC), and non-tobacco consumers (NTC), and several BioExp and BioEff were evaluated.
Results: Blood and urinary BioExp, including total nicotine equivalents and tobacco-specific nitrosamines, were higher in MSC compared to SMK. Biomarkers of combustion-related toxicants and cadmium were elevated in SMK. Elevated levels of some BioEff associated with oxidative stress (urinary isoprostanes and leukotriene E4), inflammation (white blood cell count), platelet activation (thromboxane metabolites), and lipid metabolism (apolipoprotein B100 and oxidized low-density lipoprotein) were observed in SMK relative to NTC and MSC (all p<0.05). The non-smoking groups (MSC and NTC) showed similar levels of combustion-related BioExp and BioEff.
Conclusions: Higher levels of exposure to nicotine and some N′-nitrosamines may be observed in MSC, and SMK are exposed to higher levels of combustion-related toxicants. Changes in BioEff consistent with some aspects of inflammation, oxidative stress, and altered lipid metabolism were detected in SMK compared to the non-smoking groups. The biomarker data further improve our understanding of pathophysiological changes and the risk continuum associated with various tobacco products, and could be useful components of future assessments of tobacco products.
References
1. Perfetti TA, Rodgman A. The complexity of tobacco and tobacco smoke. Beitr Tabakforsch 2011;25:215–32.Search in Google Scholar
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.Search in Google Scholar
3. U.S. Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease. A report of the surgeon general. Atlanta, GA: Centers for Disease Control and Prevention. Office on Smoking and Health, 2010.Search in Google Scholar
4. van der Vaart H, Postma DS, Timens W, Ten Hacken NH. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 2004;59:713–21.10.1136/thx.2003.012468Search in Google Scholar
5. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007;131:1557–66.10.1378/chest.06-2179Search in Google Scholar
6. Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. The chemical composition of smokeless tobacco: a survey of products sold in the United States in 2006 and 2007. Regul Toxicol Pharmacol 2012;64:367–87.10.1016/j.yrtph.2012.09.003Search in Google Scholar
7. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. J Am Med Assoc 2000;284:706–12.10.1001/jama.284.6.706Search in Google Scholar
8. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: tobacco smoke and involuntary smoking. Lyon: IARC Press, 2004.Search in Google Scholar
9. Zeller M, Hatsukami D, Strategic Dialogue on Tobacco Harm Reduction Group. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control 2009;18:324–32.10.1136/tc.2008.027318Search in Google Scholar
10. Gartner CE, Hall WD, Vos T, Bertram MY, Wallace AL, Lim SS. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet 2007;369:2010–4.10.1016/S0140-6736(07)60677-1Search in Google Scholar
11. Hatsukami DK, Joseph AM, Lesage M, Jensen J, Murphy SE, Pentel PR, et al. Developing the science base for reducing tobacco harm. Nicotine Tob Res 2007;9 Suppl 4:S537–53.10.1080/14622200701679040Search in Google Scholar
12. Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Med 2009;7:36.10.1186/1741-7015-7-36Search in Google Scholar
13. Luo J, Ye W, Zendehdel K, Adami J, Adami H-O, Boffetta P, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007;369:2015–20.10.1016/S0140-6736(07)60678-3Search in Google Scholar
14. Rodu B. Snus and the risk of cancer of the mouth, lung, and pancreas. Lancet 2007;370:1207–8.10.1016/S0140-6736(07)61533-5Search in Google Scholar
15. Royal College of Physicians. Harm reduction in nicotine addiction: helping people who can’t quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians, 2007.Search in Google Scholar
16. Britton J, Edwards R. Tobacco smoking, harm reduction, and nicotine product regulation. Lancet 2008;371:441–5.10.1016/S0140-6736(07)61482-2Search in Google Scholar
17. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005;16:347–58.10.1007/s10552-004-5519-6Search in Google Scholar PubMed
18. Piano MR, Benowitz NL, Fitzgerald GA, Corbridge S, Heath J, Hahn E, et al. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation 2010;122:1520–44.10.1161/CIR.0b013e3181f432c3Search in Google Scholar PubMed
19. Life Sciences Research Office. Scientific methods to evaluate potential reduces-risk tobacco products. Bethesda, MD: Life Sciences Research Office, 2007.Search in Google Scholar
20. Feng S, Roethig HJ, Liang Q, Kinser R, Jin Y, Scherer G, et al. Evaluation of urinary 1-hydroxypyrene, S-phenylmercapturic acid, trans,trans-muconic acid, 3-methyladenine, 3-ethyladenine, 8-hydroxy-2′-deoxyguanosine and thioethers as biomarkers of exposure to cigarette smoke. Biomarkers 2006;11:28–52.10.1080/13547500500399730Search in Google Scholar PubMed
21. Lowe FJ, Gregg EO, McEwan M. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin Chem Lab Med 2009;47:311–20.10.1515/CCLM.2009.069Search in Google Scholar PubMed
22. Sarkar M, Liu J, Koval T, Wang J, Feng S, Serafin R, et al. Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus. Nicotine Tob Res 2010;12:105–16.10.1093/ntr/ntp183Search in Google Scholar PubMed
23. Hecht SS, Yuan JM, Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol 2010;23:1001–8.10.1021/tx100056mSearch in Google Scholar PubMed PubMed Central
24. Calapai G, Caputi AP, Mannucci C, Russo GA, Gregg E, Puntoni R, et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. Basic Clin Pharmacol Toxicol 2009;104:322–8.10.1111/j.1742-7843.2008.00361.xSearch in Google Scholar PubMed
25. Zedler BK, Kinser R, Oey J, Nelson B, Roethig HJ, Walk RA, et al. Biomarkers of exposure and potential harm in adult smokers of 3–7 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers. Biomarkers 2006;11:201–20.10.1080/13547500600576260Search in Google Scholar PubMed
26. Liu J, Liang Q, Frost-Pineda K, Muhammad-Kah R, Rimmer L, Roethig H, et al. Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. Cancer Epidemiol Biomarkers Prev 2011;20:1760–9.10.1158/1055-9965.EPI-10-0987Search in Google Scholar PubMed
27. Frost-Pineda K, Liang Q, Liu J, Rimmer L, Jin Y, Feng S, et al. Biomarkers of potential harm among adult smokers and non-smokers in the total exposure study. Nicotine Tob Res 2011;13:182–93.10.1093/ntr/ntq235Search in Google Scholar PubMed
28. Faux SP, Tai T, Thorne D, Xu Y, Breheny D, Gaca M. The role of oxidative stress in the biological responses of lung epithelial cells to cigarette smoke. Biomarkers 2009;14 Suppl 1:90–6.10.1080/13547500902965047Search in Google Scholar PubMed
29. Lowe FJ, Luettich K, Gregg EO. Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective. Biomarkers 2013;18:183–95.10.3109/1354750X.2013.777116Search in Google Scholar PubMed PubMed Central
30. Campbell LR, Brown BG, Jones BA, Marano KM, Borgerding MF. Study of cardiovascular disease biomarkers among tobacco consumers, Part 1: biomarkers of exposure. Inhal Toxicol 2015;27:149–56.10.3109/08958378.2015.1013228Search in Google Scholar PubMed PubMed Central
31. Marano KM, Kathman SJ, Jones BA, Nordskog BK, Brown BG, Borgerding MF. Study of cardiovascular disease biomarkers among tobacco consumers. Part 3: evaluation and comparison with the US National Health and Nutrition Examination Survey. Inhal Toxicol 2015;27:167–73.10.3109/08958378.2015.1009196Search in Google Scholar PubMed PubMed Central
32. Nordskog BK, Brown BG, Marano KM, Campell LR, Jones BA, Borgerding MF. Study of cardiovascular disease biomarkers among tobacco consumers, Part 2: biomarkers of biological effect. Inhal Toxicol 2015;27:157–66.10.3109/08958378.2015.1013227Search in Google Scholar PubMed PubMed Central
33. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23:312–28.10.1007/s11095-005-9045-3Search in Google Scholar PubMed
34. Gregg EO, Minet E, McEwan M. Urinary biomarkers of smokers’ exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers 2013;18:467–86.10.3109/1354750X.2013.821523Search in Google Scholar PubMed PubMed Central
35. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;94:19–25.10.1161/01.CIR.94.1.19Search in Google Scholar PubMed
36. Kuusimaki L, Peltonen Y, Mutanen P, Peltonen K, Savela K. Urinary hydroxy-metabolites of naphthalene, phenanthrene and pyrene as markers of exposure to diesel exhaust. Int Arch Occup Environ Health 2004;77:23–30.10.1007/s00420-003-0477-ySearch in Google Scholar PubMed
37. Scherer G. Biomonitoring of inhaled complex mixtures – ambient air, diesel exhaust and cigarette smoke. Exp Toxicol Pathol 2005;57:75–110.10.1016/j.etp.2005.05.007Search in Google Scholar PubMed
38. Naufal ZS, Marano KM, Kathman SJ, Wilson CL. Differential exposure biomarker levels among cigarette smokers and smokeless tobacco consumers in the National Health and Nutrition Examination Survey 1999–2008. Biomarkers 2011;16:222–35.10.3109/1354750X.2010.546013Search in Google Scholar PubMed
39. Nestor TB, Gentry JS, Peele DM, Riddick MG, Conner BT, Edwards ME. Role of oxides of nitrogen in tobacco-specific nitrosamine formation in flue-cured tobacco. Beitr Tabakforsch 2003;20:467–75.10.2478/cttr-2013-0762Search in Google Scholar
40. Stephens WE, Calder A, Newton J. Source and health implications of high toxic metal concentrations in illicit tobacco products. Environ Sci Technol 2005;39:479–88.10.1021/es049038sSearch in Google Scholar PubMed
41. Marano KM, Naufal ZS, Kathman SJ, Bodnar JA, Borgerding MF, Garner CD, et al. Cadmium exposure and tobacco consumption: biomarkers and risk assessment. Regul Toxicol Pharmacol 2012;64:243–52.10.1016/j.yrtph.2012.07.008Search in Google Scholar PubMed
42. Marano KM, Naufal ZS, Kathman SJ, Bodnar JA, Borgerding MF, Wilson CL. Arsenic exposure and tobacco consumption: biomarkers and risk assessment. Regul Toxicol Pharmacol 2012;64:225–32.10.1016/j.yrtph.2012.07.007Search in Google Scholar PubMed
43. Jarup L, Akesson A. Current status of cadmium as an environmental health problem. Toxicol Appl Pharmacol 2009;238:201–8.10.1016/j.taap.2009.04.020Search in Google Scholar PubMed
44. U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress: A report of the surgeon general. Atlanta, GA: U.S. DHHS, Centers for Disease Control and Prevention, Office on Smoking and Health, 2014.Search in Google Scholar
45. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175–7.10.1164/ajrccm.162.3.2001063Search in Google Scholar PubMed
46. Suzuki J, Ogawa M, Watanabe R, Takayama K, Hirata Y, Nagai R, et al. Roles of prostaglandin E2 in cardiovascular diseases. Int Heart J 2011;52:266–9.10.1536/ihj.52.266Search in Google Scholar PubMed
47. Gomez I, Foudi N, Longrois D, Norel X. The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukot Essent Fatty Acids 2013;89:55–63.10.1016/j.plefa.2013.04.004Search in Google Scholar PubMed
48. Milne GL, Yin H, Hardy KD, Davies SS, Roberts LJ, 2nd. Isoprostane generation and function. Chem Rev 2011;111:5973–96.10.1021/cr200160hSearch in Google Scholar PubMed PubMed Central
49. Bozyk PD, Moore BB. Prostaglandin E2 and the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 2011;45:445–52.10.1165/rcmb.2011-0025RTSearch in Google Scholar PubMed PubMed Central
50. Dallongeville J, Marecaux N, Richard F, Bonte D, Zylberberg G, Fantino M, et al. Cigarette smoking is associated with differences in nutritional habits and related to lipoprotein alterations independently of food and alcohol intake. Eur J Clin Nutr 1996;50:647–54.Search in Google Scholar
51. Prasad GL, Jones BA, Schmidt E, Chen P, Kennedy AD. Global metabolomic profiles reveal differences in oxidative stress and inflammation pathways in smokers and moist snuff consumers. J Metabolomics 2015;1:2. DOI: 10.7243/2059-0008-1-2.10.7243/2059-0008-1-2Search in Google Scholar
Supplemental Material:
The online version of this article (DOI: 10.1515/cclm-2015-0594) offers supplementary material, available to authorized users.
©2016 by De Gruyter
